Related Experiment Videos
Anticardiac antibodies in hypertrophic cardiomyopathy as a marker of severity
1Department of Internal Medicine-Cardiology, Philipps-University Marburg, Germany.
Insights
This study found that most hypertrophic cardiomyopathy patients have circulating anticardiac antibodies, particularly antimyolemmal and antifibril types. However, these antibodies and patient lymphocytes did not significantly cause cell damage in hypertrophic cardiomyopathy.
Area of Science:
- Cardiology
- Immunology
- Pathology
Background:
- Hypertrophic cardiomyopathy (HCM) is a complex cardiac condition.
- The role of autoimmune mechanisms in HCM pathogenesis remains unclear.
Purpose of the Study:
- To investigate the presence and significance of anticardiac antibodies in patients with hypertrophic cardiomyopathy.
- To assess the potential for antibody-mediated or lymphocyte-mediated cardiac damage in HCM.
Main Methods:
- Analysis of peripheral blood and endomyocardial biopsies from 23 HCM patients.
- Detection of circulating immunoglobulins (IgG, IgM) and complement fixation.
- Assay for antimyolemmal and antifibril antibodies in patient sera.
- Evaluation of serum and lymphocyte cytotoxicity against cardiac cells.
Main Results:
- Immunoglobulin deposition (primarily IgG) was observed in 41% of endomyocardial biopsies.
- Antimyolemmal antibodies were detected in 78% of patient sera, and antifibril antibodies in 43%.
- Serum cytotoxicity was minimal, and lymphocytes did not show significant cytotoxic effects.
Conclusions:
- Circulating anticardiac antibodies are common in hypertrophic cardiomyopathy.
- While present, these antibodies and cellular immune responses do not appear to be major drivers of cardiac damage in most HCM patients.
- Further research is needed to fully elucidate the role of immune factors in HCM.
Abstract:
Twenty-three patients (mean age 27 years, 15 male, 8 female) with hypertrophic cardiomyopathy (10 'obstructive', 13 'non-obstructive') mostly of the sporadic type were examined for anticardiac antibodies circulating in the peripheral blood or bound in the endomyocardial biopsy. Immunoglobulin deposition in the biopsies was found in 41% of cases of the IgG isotype. IgM and complement fixation occurred less frequently. Predominant findings in the patients sera were antimyolemmal (78%) and antifibril antibodies (43%). The patients' sera were not cytolytic except for one case indicating that neither a toxic serum factor nor antibody-mediated cardiocytolysis were operative to a significant degree in hypertrophic cardiomyopathy. The patient's lymphocytes did not demonstrate a cytotoxic effect either alone or in the presence of the autologous serum.